Statistics

Total Visits

Views
Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)41

Select a period of time:

Number of views in the range

Views
Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)26

Views

Views
November 20243
December 20240
January 20251
February 20251
March 202518
April 20252
May 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
Singapore18
United States3
Spain2
Belgium1
United Kingdom1
Mexico1
 

Top cities views

Views
Council Bluffs1
Santiago de Compostela1
Victorville1